A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

NCT04672369 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Lung Cancer

Interventions

BIOLOGICAL: IBI939
BIOLOGICAL: Sintilimab

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.